Jump to content

Choose locationSutter Maternity & Surgery Center of Santa Cruz
  • Sign in or Enroll
    • Open I want to choose my medical group or hospital
    • Clear my location
Change Location
Sutter Health
  • Video Visits
  • Find Doctors
  • Find Locations
  • Treatments & Services
  • Locations
  • Sign in or Enroll
    • Video Visits
    • Find Doctors
    • Find Locations
    • Treatments & Services
    • COVID-19 Resources
    • Pay a Bill
    • Symptom Checker
    • Get Care Today
    • Health & Wellness
    • Classes & Events
    • Research & Clinical Trials
    • For Patients
    • About Sutter Health
    • Giving
    • Volunteering
    • Careers
    • News
    • For Medical Professionals
    • Other Business Services
Close Search
  • Home
  • Sutter Maternity & Surgery Center
  • Research
  • Cancer
Content

Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.

Description

Chan JK, Liang SY, Kapp DS, Chan JE, Herzog TJ, Coleman RL, Monk BJ, Richardson MT., Gynecol Oncol. S0090-8258(20)33910-X. doi: 10.1016/j.ygyno.2020.09.017. Online ahead of print., 2020 Sep 26

Investigators

Su-Ying Liang, Ph.D., Research Economist / Faculty

Abstract

We have evaluated three clinical decision points with biomarker guidance that must be made in the upfront treatment of ovarian cancer. Our discussion provides a clinical pathway to guide clinicians on the selection of new upfront regimens for ovarian cancer incorporating bevacizumab and/or poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors.

It is also important to recognize that the selection of upfront agents may influence treatment options at recurrence. For example, the addition of these novel agents may have marginal median progression-free survival (mPFS) benefit of only 3–6months; however, this clinical benefit may extend mPFS and categorize patients as “platinum-sensitive,” allow them to be eligible for the re-treatment of platinum combinations, or become eligible for more clinical trials.

Since clinicians have access to three PARPi (olaparib, niraparib, and rucaparib) in the platinum sensitive setting, they may choose to alternate the sequential use of these biologic agents from bevacizumab to PARPi or vice-versa depending on the initial response to these agents. Genetic and genomic testing serve as an important tool to triage patients towards maintenance therapy with biologic agents.

Further decision tree analysis with economic considerations are also warranted to evaluate sequential therapies beyond the upfront setting to reflect the overall ovarian cancer patient's treatment journey.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

  • Cancer
  • Disease Management
  • Genetics
  • Ovarian Cancer
  • Women's Health

Related Publications

Synergistic drug combinations from electronic health records and gene expression.

Low YS, Daugherty AC, Schroeder EA, Chen W, Seto T, Weber S, Lim M, Hastie T, Mathur M, Desai M, Farrington C, Radin AA, Sirota M, Kenkare P, Thompson CA, Yu PP, Gomez SL, Sledge GW Jr, Kurian AW, Shah NH.
J Am Med Inform Assoc. pii: ocw161. doi: 10.1093/jamia/ocw161. [Epub ahead of print]
2016 Dec 09

Improved targeting accuracy of lung tumor biopsies with scanning-beam digital x-ray tomosynthesis image guidance.

Nelson G, Wu M, Hinkel C, Krishna G, Funk T, Rosenberg J, Fahrig R.
Med Phys. 43(12):6282.
2016 Dec 01

Physicians' perceptions of shared decision-making behaviours: a qualitative study demonstrating the continued chasm between aspirations and clinical practice.

Zeuner R, Frosch DL, Kuzemchak MD, Politi MC.
Health Expect. 18(6):2465-76. doi: 10.1111/hex.12216. Epub 2014 Jun 17.
2015 Dec 01

The burden of cancer in Asian Americans: a report of national mortality trends by Asian ethnicity.

Thompson CA, Gomez SL, Hastings KG, Kapphahn K, Yu P, Shariff-Marco S, Bhatt AS, Wakelee HA, Patel MI, Cullen MR, Palaniappan LP.
Cancer Epidemiol Biomarkers Prev. 25(10):1371-1382.
2016 Oct 01

In absentia: an exploratory study of how patients are considered in multidisciplinary cancer team meetings.

Hahlweg P, Hoffmann J, Härter M, Frosch DL, Elwyn G, Scholl I.
PLoS One. 10(10):e0139921. doi: 10.1371/journal.pone.0139921. eCollection 2015.
2015 Oct 06
The Sutter Health Network of Care
Expertise to fit your needs
Primary Care

Check-ups, screenings and sick visits for adults and children.

Specialty Care

Expertise and advanced technologies in all areas of medicine.

Emergency Care

For serious accidents, injuries and conditions that require immediate medical care.

Urgent Care

After-hours, weekend and holiday services.

Walk-In Care

Convenient walk-in care clinics for your non-urgent health needs.

About Sutter

  • About Our Network
  • Annual Report
  • Awards
  • Community Benefit
  • Contact Us
  • News
  • Giving
  • Find Care

  • Birth Centers
  • Care Centers
  • Emergency Rooms
  • Hospitals
  • Imaging
  • Labs
  • Surgery Centers
  • Urgent Care
  • Walk-In Care
  • View All >
  • Featured Services

  • Behavioral Health
  • Cancer Services
  • Family Medicine
  • Home Health and Hospice
  • Orthopedics
  • Pediatrics
  • Pregnancy
  • Primary Care
  • Women's Health
  • View All >
  • Patient Resources

  • Accepted Health Plans
  • Classes and Events
  • Estimate Costs
  • Health and Wellness
  • Medical Records
  • Medicare Advantage
  • My Health Online
  • Pay a Bill
  • Symptom Checker
  • Our Team

  • For Employees
  • Physician Careers
  • Recruiting Events
  • Residencies and Fellowships
  • Sutter Careers
  • Vendors
  • Volunteers
    • ADA Accessibility
    • Contact
    • Privacy
    • Do Not Sell My Personal Information

    • LinkedIn Opens new window
    • YouTube Opens new window
    • Facebook Opens new window
    • Twitter Opens new window
    • Glassdoor Opens new window
    • Instagram Opens new window

    Copyright © 2022 Sutter Health. All rights reserved. Sutter Health is a registered trademark of Sutter Health ®, Reg. U.S. Patent & Trademark office.

    Cookie Policy

    We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences

    Privacy Policy Cookie Preferences